News

Dec 26, 2023

ASCO showcased payoff for new cancer medicines: longer lives

By Matthew Herper , Angus Chen , Adam Feuerstein and Katherine MacPhailJune 7,

By Matthew Herper , Angus Chen , Adam Feuerstein and Katherine MacPhailJune 7, 2023

CHICAGO — Well, that's a wrap. The biggest meeting in cancer research — and, really, one of the biggest annual conferences for the pharmaceutical industry as a whole — has drawn to a close. What did we learn from this year's annual meeting of the American Society of Clinical Oncology?

Here's one lesson: New cancer medicines, given enough time, can be shown to affect the thing patients care about most — whether they live or die. The biggest example came with results of Tagrisso in non-small cell lung cancer that is still early enough to be surgically removed. In patients with a particular genetic mutation, the drug cut the death rate in half. And that was the result of a decade-and-a-half of work by researchers at the drug's maker. STAT had the story of Susan Galbraith, AstraZeneca's head of cancer research, and her role in making that happen.

advertisement

About a decade ago researchers started to get excited about another new technology: CAR-T, in which a patient's white blood cells are engineered to attack tumors. Earlier this year, one of the first children cured with this tech, Emily Whitehead, spoke at a STAT event. Now she's 18. At ASCO, we got statistical proof that patients with B-cell lymphoma who got Yescarta, a CAR-T made by Gilead, lived longer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

Senior Writer, Medicine, Editorial Director of Events

Matthew Herper covers medical innovation — both its promise and its perils.

Cancer Reporter

Angus Chen is a cancer reporter at STAT.

Senior Writer, Biotech

Adam Feuerstein is STAT's national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Programmer, Editorial Events

ASCO23

biotechnology

cancer

drug development

pharmaceuticals

STAT+

This name will appear with your comment

There was an error saving your display name. Please check and try again.